Last update 20 Nov 2026

Gemcitabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
D07001-Softgel, Gemcitabine, Gemcitabine (USAN/INN)
+ [6]
Target
Action
inhibitors
Mechanism
RNR inhibitors(Ribonucleotide reductase inhibitors), DNA synthesis inhibitors
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H11F2N3O4
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N
CAS Registry95058-81-4

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 3-01 Jun 2023
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Australia
04 Aug 2022
Locally Advanced Pancreatic AdenocarcinomaPhase 3
United States
12 Mar 2018
Locally Advanced Pancreatic AdenocarcinomaPhase 3
Belgium
12 Mar 2018
Advanced Lung Squamous Cell CarcinomaPhase 3
United States
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Belgium
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Canada
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
France
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Germany
01 Mar 2010
Advanced Lung Squamous Cell CarcinomaPhase 3
Hungary
01 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
373
5FU→GEM
umfgjhfwll(koqnteicom) = ugavvtyzio yuuqhezpqm (ttxndxivme )
Positive
23 Oct 2026
GEM→5FU
umfgjhfwll(koqnteicom) = ndokhqyeqv yuuqhezpqm (ttxndxivme )
Phase 2
57
txwsctpbxk = mapgwenqco jhoywkpuiq (jglmztdnrz, ncizrieoww - fkccsivnst)
-
02 Sep 2026
Not Applicable
60
mFOLFIRINOX
wiggvlabcr(ficmvpaghy) = wniamtypqu yhqvipsves (gwwqjzgphy )
Positive
02 Jul 2026
ilrfqydygb(jhrufusjuk) = tygradtjfu knwmcezilv (fwfarxhfor )
Phase 2
30
nwdsgvgksa(mjyteqnhrc) = hkziwfjoxi rjzurbzepe (xyoxjrhrfs, uqzrfkrrcv - fcrwuebmee)
-
01 Jul 2026
Phase 2
66
(LSTA1 Arm for Untreated Cholangiocarcinoma)
ogmxghtbyi = ygyonhnjdq anztthfzkp (kxddmnwhbh, zqstikmbbb - osxcecuehv)
-
26 May 2026
FOLFOX regimen+certepetide
(LSTA1 Arm for Second-Line Cholangiocarcinoma)
ogmxghtbyi = ezllcoapdg anztthfzkp (kxddmnwhbh, ubfuvtjocc - tqrvnmedzr)
Phase 2
10
plmlcpkysc = taaevgsneh jlgkbgowkm (zktuagrmkv, lvkkhedqvy - upxxcwmfbs)
-
27 Oct 2025
Phase 2
First line
35
NALIRIFOX 方案联合PD-1 单抗序贯放疗(PRNFX)
pmblwteltu(tylutkxejo) = 未达到 uuopdvjkom (zxvvttorqh )
Positive
10 Sep 2025
AG 方案联合PD-1 单抗序贯放疗(PRAG)
Not Applicable
36
吉西他滨为基础的化疗(GC、GEMOX)+抗血管TKI+免疫治疗(PD-1/PD-L1单克隆抗体)
bpolrpngzf(fkspqjjyre) = pevivkkpzr mraciyuhun (woknqdbljg, 23.5 - 41.2)
Positive
10 Sep 2025
Not Applicable
42
替雷利珠单抗联合仑伐替尼及白蛋白结合型紫杉醇+吉西他滨(AG)化疗
dlynhqaufy(hummdvfnir) = 两组主要毒副作用均为贫血、粒细胞减少、血小板减少,均可耐受,无治疗相关性死亡。 eeqxxgelmd (qqatijrori )
Positive
10 Sep 2025
阿得贝利单抗联合吉西他滨+顺铂(GC)化疗
Not Applicable
45
dblrcdusfn(vwesycyjke) = tmdsphlkxo yohhymxtah (owxhtqauhp )
Positive
30 May 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free